Jorge A Marrero
Overview
Explore the profile of Jorge A Marrero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
13383
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singal A, Quirk L, Boike J, Chernyak V, Feng Z, Giamarqo G, et al.
Hepatology
. 2024 Dec;
PMID: 39699563
HCC surveillance is recommended by liver professional societies but lacks broad acceptance by several primary care and cancer societies due to limitations in the existing data. We convened a diverse...
2.
Cholankeril G, Thrift A, Khaderi S, Kanwal F, El-Serag H, Duong H, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39694208
No abstract available.
3.
El-Serag H, Thrift A, Duong H, Ning J, Khaderi S, Singal A, et al.
Hepatol Commun
. 2024 Dec;
8(11).
PMID: 39652379
Background: Previous studies have reported higher circulating bile acid levels in patients with HCC compared to healthy controls. However, the association between prediagnostic bile acid levels and HCC risk among...
4.
Fujiwara N, Lopez C, Marsh T, Raman I, Marquez C, Paul S, et al.
Gastroenterology
. 2024 Nov;
168(3):556-567.e7.
PMID: 39521255
Background & Aims: Hepatocellular carcinoma (HCC) risk stratification is an urgent unmet need for cost-effective HCC screening and early detection in patients with cirrhosis to improve poor HCC prognosis. Methods:...
5.
Singal A, Parikh N, Kanwal F, Marrero J, Deodhar S, Page-Lester S, et al.
Hepatol Commun
. 2024 Nov;
8(11.
PMID: 39495136
Background: Professional guidelines recommend HCC screening in at-risk patients using semi-annual ultrasound with or without alpha-fetoprotein (AFP); however, this strategy has limited effectiveness due to low adherence and sensitivity. Increasing...
6.
Marsh T, Parikh N, Roberts L, Schwartz M, Nguyen M, Befeler A, et al.
Gastroenterology
. 2024 Sep;
168(2):316-326.e6.
PMID: 39293548
Background & Aims: Better surveillance tests for hepatocellular carcinoma (HCC) are needed. The GALAD score (gender, age, α-fetoprotein [AFP] L3, AFP, and des-γ carboxyprothrombin) has been shown to have excellent...
7.
El-Serag H, Jin Q, Tayob N, Salem E, Luster M, Alsarraj A, et al.
Hepatology
. 2024 Jun;
81(2):465-475.
PMID: 38899967
Background And Aims: The original hepatocellular carcinoma early detection screening (HES) score, which combines alpha-fetoprotein (AFP) with age, alanine aminotransferase, and platelets, has better performance than AFP alone for early...
8.
Hassan M, Li D, Han Y, Byun J, Hatia R, Long E, et al.
Hepatology
. 2024 Feb;
80(1):87-101.
PMID: 38381705
Background And Aims: Despite the substantial impact of environmental factors, individuals with a family history of liver cancer have an increased risk for HCC. However, genetic factors have not been...
9.
El-Serag H, Kanwal F, Ning J, Powell H, Khaderi S, Singal A, et al.
Gut
. 2024 Feb;
PMID: 38365278
Background: Inflammatory and metabolic biomarkers have been associated with hepatocellular cancer (HCC) risk in phases I and II biomarker studies. We developed and internally validated a robust metabolic biomarker panel...
10.
Ochoa-Allemant P, Marrero J, Serper M
Hepatol Commun
. 2023 Dec;
7(12).
PMID: 38051551
Background: The global liver community established a more precise criteria to characterize steatotic liver disease (SLD), specifically metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated and alcohol-associated liver disease...